纯化供者CD34(+)细胞输注治疗单倍型造血干细胞移植后移植物功能不良12例临床分析

OBJECTIVE: To evaluate the efficacy and safety of purified CD34(+) stem cell boost in the treatment of poor graft function (PGF) after allogeneic hematopoietic stem cell transplantation (HSCT). METHODS: 12 patients with poor graft function, reported in our hospital during January 2014 to March 2018, were retrospectively analyzed; The donors of 12 patients were HLA mismatched family members, and all treated with donor purified CD34(+) stem cell after G-CSF mobilization, calculating and statistical analyzing the purity of separation and the recovery rate of CD34(+) stem cells. The related complications and the recovery of blood cells after infusion were observed. RESULTS: The purity of CD34(+) cells in the separation products was 92.0% (44.0%–97.0%), and the recovery rate was 55.0% (45.0%–96.7%). The median number of CD34(+) cells was 1.9 (0.9–4.4)×10(6)/kg with CD3(+) cells as 0.6 (0.3–2.0)×10(4)/kg. The median durations of white blood cells, platelet and red blood cells recoveries were 18 (14–39), 29 (16–153) and 60 (9–124) days, respectively. All 12 patients didn't experience serious adverse reactions in the process of infusion, 10 patients achieved hematopoietic recovery, 1 case partial remission, 1 case no recovery, without occurrence of aggravated infection, graft versus host disease and other complications. CONCLUSION: The infusion of donor purified CD34(+) stem cell was a safe and effective method for PGF after allogeneic HSCT.